Abstract: ob＜x＞jective: To investigate the effects of high-frequency repetitive transcranial magnetic stimulation (rTMS) on depression, anxiety and quality of life in patients with Parkinson’s disease. Methods: 58 patients with Parkinson’s disease who were admitted to Xuzhou Renci Hospital from October 2019 to June 2022 were selected, and they were accompanied with depression and anxiety. According to the random numbe r table 1:1, they were assigned to the rTMS treatment group (high-frequency 5HZ+conventional anti PD drugs) and the control group (antidepressant and anxiety drugs+conventional anti PD drugs), and compared the depression and anxiety, Hoehn Yahn (H-Y) staging and quality of life scores of patients who were at the end of followed up 14 days of treatment, follow-up 30 days and 90 days before treatment. Results: At the end of 14 days of treatment and after 30 days of treatment, the scores of HAMD, HAMA and PDQ-39 in the two groups were lower than those before treatment, and the rTMS treatment group was lower than that in the control group, the difference was statistically significant (P<0.05). After 90 days of follow-up, the scores of HAMD and PDQ-39 in the two groups were lower than those before treatment, with a statistically significant difference (P<0.05). There was no significant difference in Hoehn Yahn (H-Y) staging between the two groups before treatment and at the end of 14 days of treatment, 30 days of follow-up and 90 days of follow-up (P>0.05). Conclusion: High frequency repetitive transcranial magnetic stimulation (rTMS) can significantly improve the symptoms of depression, anxiety and quality of life in patients with Parkinson’s disease, and has high safety.